Subgroups

Bayer HealthCare

| 1 - 20 | 21 - 40 | 41 - 60 | 61 - 80 | 81 - 82 |

Thursday - October 29, 2009
On top of the world
Geri Winkler and the Turquoise Goddess
Diabetic climbs Cho Oyu, the sixth-highest mountain on Earth (8,201 meters)
Wednesday - October 28, 2009
European Journalists’ Prize 2009 announced
Association of German Medical Journalists (VDMJ) and Bayer HealthCare honor good medical reporting
Tuesday - October 27, 2009
Bayer AG News Conference Call and Report for the Third Quarter of 2009
Tuesday - October 27, 2009
Renewed year-on-year growth in underlying EBITDA in the third quarter of 2009:
Bayer back on the uptrend
HealthCare again strong – weak quarter at CropScience – MaterialScience substantially improved / Group sales EUR 7,392 million (minus 7.0 percent) / EBITDA before special items EUR 1,499 million (plus 0.4 percent) / Net income EUR 249 million (minus 10.1 percent) / Net cash flow EUR 1,517 million (plus 22.9 percent) / Full-year Group forecast confirmed
Friday - October 23, 2009
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Patients with Non-Responsive Thyroid Cancer
Thursday - October 22, 2009
Swiss regulatory authority Swissmedic announces results of its analysis of current studies on the risks of hormonal contraceptives:
The risk of venous thromboembolism for drospirenone containing oral contraceptives is comparable to the risk of other oral contraceptives available on the market
Thursday - October 8, 2009
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer´s disease
Florbetaben will be used for the very first time in Alzheimer´s patients being treated with a vaccination therapy
Monday - October 5, 2009
Phase-III data presented at the World Congress of Gynecology & Obstetrics (FIGO):
Bayer’s novel oral contraceptive Qlaira® significantly reduces heavy menstrual bleeding
Results also confirm significant improvement in blood iron levels
Wednesday - September 30, 2009
Results Reported for Exploratory Phase II Trial of Nexavar in Combination with Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Preliminary results require further analysis and interpretation
Monday - September 28, 2009
DIDGET connects directly to Nintendo DS:
First blood glucose designed especially for children
Helping kids to manage their diabetes / Based on Bayer’s trusted Contour technology
Monday - September 28, 2009
Contour USB: Plug in, gain instant knowledge, take action:
First blood glucose monitor with Plug & Play Diabetes Management Software
Bright color display screen / Rechargeable battery / Instructive text messages in native languages / Based on Bayer’s trusted Contour technology
Wednesday - September 23, 2009
Phase II Study in Advanced Breast Cancer:
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
First presentation of results at joint ECCO-ESMO congress in Berlin, Germany
Tuesday - September 22, 2009
Leading-edge medical research and development:
Bayer researchers nominated for the “Deutscher Zukunftspreis” awarded by the German Federal President
Development of the novel anticoagulant rivaroxaban commended / Three research and development teams on shortlist
Tuesday - September 22, 2009
Contribution to the fight against tropical diseases
Bayer to supply WHO with a product for the combination therapy of African sleeping sickness
New combination therapy added to the WHO's Essential Drug List
Tuesday - September 22, 2009
Results of a Phase II study in Renal Cell Carcinoma (RCC):
Bayer’s Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
Presentation of complete results at joint 15th ECCO and 34th ESMO Multidisciplinary Congress / Confirmation of topline data presented at ASCO 2009
Thursday - September 17, 2009
Joint 15th ECCO and 34th ESMO Multidisciplinary Congress:
Bayer Announces New Data on Oncology Portfolio To Be Presented at the ECCO-ESMO Congress 2009
Marketed Products and Pipeline Compounds Highlighted at Presentation Sessions
Tuesday - September 15, 2009
Bayer Supervisory Board decides company’s future management line-up:
Dr. Marijn E. Dekkers to be new CEO of Bayer from October 1, 2010
Werner Wenning extends his contract by eight months / CFO Klaus Kühn to retire on April 30, 2010 / Werner Baumann to be new CFO / BHC CEO Arthur J. Higgins to leave Bayer at his own request
Thursday - September 10, 2009
European Multiple Sclerosis Congress ECTRIMS:
Recent Research Supports the Importance of Starting Treatment Early in Patients with Multiple Sclerosis (MS)
New data show impact of hidden symptoms in early MS
Thursday - September 10, 2009
New data presented at European Multiple Sclerosis Congress ECTRIMS:
Betaferon® may play a role in the protection of brain tissue
Friday - September 4, 2009
Mastering the challenge
Conquering the summit unaided
Diabetic Geri Winkler plans to scale Cho Oyu without the help of supplemental oxygen

| 1 - 20 | 21 - 40 | 41 - 60 | 61 - 80 | 81 - 82 |